Research programme: nanopolymer-conjugated anticancer drugs - Rexahn Pharmaceuticals

Drug Profile

Research programme: nanopolymer-conjugated anticancer drugs - Rexahn Pharmaceuticals

Alternative Names: HPMA-docetaxel-folate; HPMA-gemcitabine; Nanopolymer anticancer drugs; RX-21101; RX-21202

Latest Information Update: 22 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Drug conjugates; Polymers; Pyrimidine nucleosides; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 18 Jan 2018 Preclinical development is ongoing in Breast-cancer, Non-small cell lung cancer, Ovarian cancer and Prostate-cancer
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top